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Abstract
Background: Definitive post mortem confirmation of intoxication by the neurotoxic rodenticide bromethalin can
be challenging. Brain lesions are not specific and detection of bromethalin and its metabolites are unpredictable
due to rapid photodegradation and inconsistent behavior in tissues.
Case presentation: A 2-year-old dog presented with rapid onset of severe muscle tremors and death within hours
after a known ingestion of a reportedly low dosage of bromethalin and subsequent decontamination using activated
charcoal. Marked meningeal hemorrhages and multifocal myelin sheath vacuolation were observed in the brain. A
marked reactive astrocytosis and neuronal hypoxia/necrosis were identified using immunohistochemistry (IHC) for glial
fibrillary acidic protein (GFAP) and for neuron specific protein (NeuN). Bromethalin exposure and tissue
absorption was confirmed by identification of one of two isomeric 543.7 molecular weight (MW) breakdown
products in the patient’s adipose and kidney samples using gas chromatography (GC) combined with tandem
quadrupole mass spectrometry (MS/MS).
Conclusions: The severity of clinical signs and subsequent death of this dog was not expected with the low
dosage of bromethalin reportedly ingested, and the use of activated charcoal possibly precipitated a hypernatremic
status. Meningeal hemorrhages are atypical of bromethalin intoxication, and might have been caused by hyperthermia,
secondary to tremors or hypernatremia. Identification of one of two isomeric breakdown products in the adipose tissue
and kidney provides an additional molecule to the toxicologic testing regime for bromethalin intoxication.
Background
Bromethalin is a potent neurotoxic rodenticide, devel-
oped in the late 1970’s to combat rodent resistance to
anticoagulant rodenticides [1]. Ingestion of rodent baits
by companion animals is a common toxicologic emer-
gency, and may become more frequently observed with
a recent ban of second generation anticoagulant rodenti-
cides, limiting the options for effective products available
to consumers [1, 2]. There is no specific antidote for
bromethalin intoxication and clinical signs in dogs are
typically dependent on the dose involved. Large doses
(2.38-5.6 mg/kg, LD50: 4.7 mg/kg in the dog) lead to an
acute onset of clinical signs (within 2 to 12 hours)
including severe muscle tremors, seizures, hyperesthesia,
hyperexcitability and death due to respiratory paralysis
[3]. Lower doses tend to exhibit a prolonged time course
with clinical signs developing 2–4 days after ingestion.
These signs may mimic those seen with spinal cord com-
pression secondary to disc disease (ataxia progressing to
decreased proprioception, loss of deep pain response,
upper motor neuron urinary signs), and may progress over
1–2 weeks to include muscle tremors, hyperexcitability,
rigidity, seizures, coma and death [3]. The lowest pub-
lished dose leading to clinical signs and death in a dog is
0.45 mg/kg [2]. Interestingly, similar clinical signs have
also been described in a human intoxicated with low dose
of bromethalin [4].
Treatment is typically focused on decontamination
(including administration of activated charcoal), moni-
toring for the development of clinical signs, and pro-
viding supportive care. Paradoxically, in our case the
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administration of activated charcoal could have precipi-
tated the disease by inducing hypernatremia.
Confirmation of bromethalin intoxication can be chal-
lenging as bromethalin is rapidly photodegraded [3].
Because tissues samples collected at necropsy are not
typically protected from light, and toxicologic analyses
are not performed in dark rooms, as well as for other
unknown causes, tissue residues are often of too low a
concentration to be detected by conventional methods,
i.e. Selected Ion Monitoring (SIM) or full scan data ac-
quisition from single quadrupole gas chromatography/
mass spectrometry (GC/MS). Tandem quadrupole mass
spectrometry offers a highly sensitive means of detecting
bromethalin breakdown products due to its significant
reduction of background interference by the second
quadrupole as well as the enhanced specificity offered by
the breakdown products’ exceptionally high mass/charge
(m/z) ratios. It likely offers several orders of magnitude
greater sensitivity than SIM on single quadrupole GC/
MS and was therefore deemed an appropriate detector
following gas chromatography (GC).
Case Presentation
A 5.9 kg, 2- year-old, female spayed, mixed breed dog was
submitted to the Veterinary Teaching Hospital emergency
service for ingestion of 1 to 1.5 bricks containing 0.01 % bro-
methalin mouse bait (Tomcat brand, Motomco, Madison
WI) between 3–7 hours earlier that day. The patient was clin-
ically normal on presentation and clinical chemistry parame-
ters, including electrolytes, were within normal limits. Per
consult with animal poison control, the estimated dose of
bromethalin was determined to be low (0.8 mg/kg) and de-
contamination with close monitoring for development of
clinical signs was deemed appropriate therapy. Emesis was
induced and a small amount of mouse bait was produced.
A 20 % intravenous fat emulsion (Intralipid® manufactured
by Fresenius Kabi, Uppsala, Sweden for Baxter Healthcare
Corporation, Clintec Nutrition Division, Deerfield, IL
60015 USA) was administered as an 1.5 ml/kg bolus given
IV over 15 minutes then 0.5 ml/kg/min for 30 minutes as
a constant rate infusion. Activated charcoal (130 mls of
ToxiBan® Lloyd, Inc, Shenandoah, IA 51601, USA) con-
taining 104 mg of activated charcoal/ml and 62.5 mg kao-
lin/ml, with an unspecified concentration of preservatives,
suspending agents and water was administered orally. The
patient was discharged.
This was a case presentation regarding theemergent
veterinary treatment of a poisoned canine with subse-
quent post-mortem analysis of tissues. Allwork was per-
formed under the consent of the animal’s owner and was
not a part of a funded research study. No experimental
research was performed that would require the approval
of the University of Illinois ethicscommitte.
Results
Case outcome
After returning home, the patient’s owners noticed the
development of slight ataxia. As instructed, they returned
to the emergency room, 2 hours after the initial presenta-
tion. The patient re-presented with severe muscle tremors,
rigidity, and nystagmus. The patient was administered
1 mg/kg of diazepam rectally and then 0.5 mg/kg intra-
venously (Hospira Inc, Lake Forest, IL 60045 USA). Dur-
ing these stabilization efforts she became acutely cyanotic
and rigid. Cardiac auscultation revealed bradycardia with
a faint heart beat and pulse deficits. She was intubated
and atropine 0.04 mg/kg (Butler Schein Animal Health,
Dublin, OH 43017, USA), and two doses of epinephrine
0.01 mg/kg (IMS Limited, South El Monte, CA 91733,
USA) were administered intravenously, though she failed
to respond and was found to be in asystole. During CPR
and for at least 45 minutes after death, the animal
remained in rigid extension. A venous blood sample, col-
lected minutes before death, revealed sodium concentra-
tion of 168 mmol/L (normal values 144–151 mmol/L).
Post mortem findings, histopathology and IHC analysis
At necropsy the stomach and entire intestinal tract were
filled with activated charcoal. The meninges were diffusely
red to dark red, wet and gelatinous (hemorrhagic) (Fig. 1a).
Histologically, neurons within the cortical grey matter were
occasionally, multifocally slightly shrunken and hypereosi-
nophilic suggesting hypoxia and necrosis (Fig. 1b). The sur-
rounding neuropil was pale and multifocally vacuolated
(spongiosis). Cerebral and meningeal blood vessels were se-
verely congested. The leptomeninges were diffusely and
markedly expanded by hemorrhage (Fig. 1d).
Histological sections (5 μm) were dewaxed, rehydrated
in water and then used for standard immunohistochemical
analyses as previously described [5, 6]. Briefly, each section
was incubated with one of the primary antibodies (GFAP
Dako Z0334 1/500; NeuN Abcam ab177487 1/1000). An
adequate secondary biotinylated antibody (Jackson Labora-
tory, Bar Harbor, Maine) and avidin–biotin–peroxidase
complex system (ABC Vector Laboratories, Burlingame,
CA, USA) were used to detect primary antibodies. DAB-
NiCl (Vector, black deposits) and AEC (Vector, red de-
posits) were used as chromogens. A slight counter-staining
was done using aqueous hematoxylin. Nonspecific binding
was controlled by omitting the primary antibody, and using
other primary antibodies as isotypic controls.
IHC revealed marked increase in reactivity of astro-
cytes for GFAP, compared to controls with enlargement
of astrocyte soma, and increased astrocytic processes
(astrocytosis) perivascularly and within the glia limitans
(Fig. 1c-f). Neurons within the cortical grey matter
exhibited moderate to marked decreased reactivity for
NeuN compared to controls (Fig. 1c-f).
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Within white matter tracts of the cerebrum, internal
capsule, cerebellum and brainstem, the myelin sheaths
were multifocally swollen with variably sized, clear
vacuoles that occasionally contain scant amounts of finely
fibrillar, eosinophilic material (fragmented myelin) (Fig. 2a).
Compare to a control brain sample (Fig. 2b), astrocytes
within the adjacent cortical gray matter were frequently
swollen, and exhibited astrocytosis as previously described
(Fig. 2c).
Toxicologic analyses
To confirm absorption of bromethalin, tissue samples
including adipose, liver, kidney, and brain were submit-
ted for toxicologic evaluation. All tissues were initially
screened for bromethalin and desmethylbromethalin by
simple and less sensitive gas chromatography mass spec-
trometry (GC-MS) and SIM or Full Scan methodologies.
The instrument was an Agilent 7890–5975 GC/MS





Fig. 1 Brain, cortical lesions. a Gross image of brain at necropsy showing marked meningeal congestion and hemorrhages. b In the cortical grey
matter are shrunken and hypereosinophilic neurons as well as mild vacuoles of the neuropil (spongiosis), H&E stain 400x. c and e) Control canine brain
IHC for GFAP (red) and NeuN (black). Note intense black stain of normal neurons and scattered red staining of normal, resting astrocytes (100x and
400x). d and f): IHC for GFAP and NeuN on brain sections from the bromethalin intoxicated dog: Note marked decrease in NeuN (black) staining in
neurons compared to control and increase in GFAP (red) indicating enlargement of astrocyte cell bodies and astrocytic processes in the glia limitans.
(100x and 400x)
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impact ionization. All samples were negative based on this
initial screen. Subsequently, a recently developed gas chro-
matography tandem quadrupole mass spectrometric (GC-
MS/MS) Multiple Reaction Monitoring (MRM) method
was developed with an Agilent 7890–7000 GC-MS/MS
capable of positive mode electron-impact ionization and
equipped with an Agilent Multi-Mode Inlet. This method
is sensitive for bromethalin breakdown products and
provides additional surrogate markers to screen for
bromethalin exposure. In short, the instrumentation
enabled generation of MRM settings for bromethalin
breakdown products of molecular weights 231, 311,
327, 453, 517, 532, 543 and 547 whose spectra and
additional information will be described in a forth-
coming article on bromethalin analysis. The most sig-
nificant and recurring products were two 543.7 MW
compounds to either side of the bromethalin chromato-
graphic peak. Each compound represents loss of a methyl
group and a molecule of hydrogen fluoride, and one of
these structures has been previously described as arising
via chemical ionization mass spectrometry (Pasquale-
Styles, et al., 2006). MRM settings for these 543.7 MW
products were derived by measuring product ions from
principal peaks of the compound and then optimizing col-
lision energies for each resulting transition. MRM settings
are listed in Table 1. The 543.7 MW breakdown products
are of interest in that desmethylbromethalin standard can
generate one of the breakdown products, whereas
bromethalin standard generates both of them. See Table 2
for the breakdown seen from compound standards. This
implies that one of the products can arise from a
demethylated intermediate, whereas it is likely that the
second one requires the participation of the bromethalin
methyl group. It remains to be determined whether the
compounds exist as such in sample extracts or in fact are
gas chromatographic or even electron impact derived side
products from other intermediates, such as from des-
methylbromethalin. The operational limits of detection
for both bromethalin and desmethylbromethalin were
10 ppm in tissue samples.
a b c
Fig. 2 Brain (internal capsule) from dog after bromethalin ingestion and activated charcoal administration. a H&E stained section of the intoxicated
dog showing vacuolization of myelin sheaths (400x). b Control brain white matter stained for GFAP (red) (400x). c White matter of canine brain after
bromethalin ingestion IHC for GFAP (red), note increased astrocyte cell bodies and astrocytic processes (400x)
Table 1 Multiple reaction monitoring (MRM) settings on the GC/MS/MS for bromethalin, desmethylbromethalin and bromethalin’s
543.7 MW breakdown products
Origin Precursor, m/z Product, m/z Dwell, msec Collision energy, eV
Bromethalin 543.7 mw breakdown product 543 512.5 10 15
Bromethalin 543.7 mw breakdown product 543 405.5 10 30
Bromethalin 543.7 mw breakdown product 399 239 10 35
Bromethalin 577 468 10 10
Bromethalin 468 448 10 10
Bromethalin 468 405 10 30
Bromethalin 226 199 10 25
Desmethyl Bromethalin 563 69 10 20
Desmethyl Bromethalin 313 232 10 5
Desmethyl Bromethalin 311 182 10 35
Desmethyl Bromethalin 231 204 10 20
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The GC-MS/MS method made use of tissue extracts
prepared in accordance with a previously described
method [7]. Briefly, 10 g of sample was mixed with 5 mL
1 N sodium hydroxide and allowed to sit for 5 min then
extracted with 100 mL methylene chloride in a 250 mL
separatory funnel. 10 mL of 0.1 N sulfuric acid was
added to the methylene chloride eluate in a stoppered
graduate cylinder and mixed thoroughly. The methylene
chloride organic phase was passed through a funnel con-
taining sodium sulfate to remove any water. The organic
phase was reduced to 1 mL under a constant stream of
nitrogen. The extract was resuspended to a final volume
of 4 mL with 1:1 methylene chloride:cyclohexane and
purified by gel permeation chromatography (GPC). The
fraction eluting from 130 to 200 mL was reduced to
3 mL by rotary evaporator then taken to dryness under a
constant stream of nitrogen. The sample was resus-
pended in 100 uL methanol in a small vial to be ana-
lyzed by gas chromatography tandem quadrupole mass
spectrometry (GC-MS/MS).
Bromethalin analytical standard was generously sup-
plied by the US Environmental Protection Agency
(US EPA) National Pesticide Standard Repository.
Desmethylbromethalin standard was from Toronto Re-
search Chemicals (Toronto, Ontario, Canada). IUPAC
chemical names were obtained by use of ChemDraw
Professional software version 15.0.0.106 (Perkin Elmer,
Waltham, MA). Analytical screening of bromethalin,
desmethylbromethalin, and physicochemical breakdown
products in adipose fat, brain, kidney, liver, and stomach
content was performed by GC-MS/MS using two 15 m ×
0.250 mm × 0.25 um DB5-MS capillary columnsi joined
with a “T” configuration to enable post-run backflushing.
The GC oven temperature was held at 15 °C for 3 minutes
and then ramped to 260 °C at a rate of 20 °C/minute The
oven temperature was maintained for 10 minutes then
increased at 60 °C/minute to 320 °C (held 8-minutes) for a
total run time of 27.5 minutes. Helium was used as the car-
rier gas with an inlet pressure of 18.1 psi. The inlet config-
uration was set to pulsed splitless mode and 5 uL of sample
was injected for analysis. The inlet temperature was held at
130 °C for 1 min. and then ramped to 325 °C at a rate of
600 °C/min for 5 min. The transfer line temperature was
set to 280 °C. The collision cell used helium as the quench
gas at 2.25 mL/min, nitrogen as the collision gas at 1.5 mL/
min, and a collision energy ranging from 5 to 35 volts de-
pending on analyte. Results for kidney and adipose samples
as well as a spiked liver control are shown in Fig. 3a. The
positive control for this study consisted of unexposed
bovine liver spiked with bromethalin in methanolic solution
to 100 ppm. The negative control was the same liver matrix
treated with solvent only, and its examination produced a
flat baseline in comparison to the chromatographic peaks
seen in the spike or samples (result not shown).
In the adipose and kidney samples provided for this
case, a 543.7 MW breakdown product of molecular for-
mula C13H4N3O4F2Br3 provided analytical evidence for
bromethalin exposure (Fig. 3b,c). Figure 4 illustrates the
likely origin of the two different 543.7 MW (nominal
MW 541) bromethalin breakdown products. Both liver
and brain were negative for bromethalin, desmethylbro-
methalin, and either breakdown product. Novel peaks
were assigned by inference that compounds with tribro-
minated isotopic abundance patterns surrounding the
molecular ion could only have arisen from bromethalin
either in standards of bromethalin or in spiked liver
samples (spectra not shown).
Discussion
Bromethalin is a highly liposoluble compound that is
rapidly absorbed after ingestion, undergoes enterohepatic
circulation, and readily crosses the blood brain barrier. It
is metabolized by P450 enzymes to its active metabolite
desmethylbromethalin which uncouples oxidative phos-
phorylation in mitochondria, leading to a rapid decline in
available ATP [8]. Subsequently, Na+/K+ pumps fail as
their activity is dependent on energy derived from ATP.
Increased intracellular sodium concentrations lead to
cellular edema due to the passive influx of water through
the plasma membrane, splitting of the myelin sheaths, and
increased CSF pressure leading to neurologic signs and
death [3, 8, 9]. In our case, the amount of bromethalin re-
ported to be ingested by the owner was estimated to be
low (0.8 mg/kg) and should have resulted in either no
clinical signs or development of signs over several days.
However, multiple factors support bromethalin’s role in
this case including the nature of the clinical signs, persistent
rigidity prior to death (suggesting loss of ATP function), as
Table 2 Principal breakdown products arising from desmethylbromethalin and bromethalin and their relative amounts based on
total ion chromatograph area in standards run at 100 and 1000 ppm. RRT = relative retention time, relative to that of bromethalin
Compound Desmethyl-bromethalin DHFDMB-I Bromethalin DHFDMB-II
RRT 0.83 0.85 1.00 1.02
Bromethalin 8.2 % 91.2 % 0.6 %
Std dev +/- 1.7 % +/- 1.7 % +/- 0.03 %
Desmethylbromethalin 98.8 % 1.2 %
Std dev +/- 0.7 % +/- 0.7 %
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b
Positive liver control sample
Kidney sample from our case
Adipose sample from our case
Fig. 3 (See legend on next page.)
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well as finding breakdown products of bromethalin in the
animal’s tissue. One hypothesis for the sudden onset of
severe clinical signs in this case is that the dog actually
ingested either a larger amount of the mouse bait than was
reported by the owner, or ingested additional bait days prior
to the owner noticing. A likely alternative option is that the
use of activated charcoal contributed to the acute develop-
ment of the neurologic disorder. It has been reported that
activated charcoal administration can lead to rare idiosyn-
cratic hypernatremias in approximately 0.6 % of cases in
humans (>155 mmol/L) [10, 11] and has been anecdotally
reported as a rare occurrence in dogs [12].
Abrupt changes in natremic status can have devastat-
ing, even fatal neurologic consequences in a wide variety
of animal species including humans, dogs, pigs, poultry
and ruminants. Typical lesions include osmotic demye-
lination syndromes (e.g. abrupt increase in natremia to
treat a hyponatremic status) or cortical laminar necrosis
(e.g. salt intoxication/water deprivation/water intoxication
that lead to an abrupt decrease in natremia after a hyper-
natremic status). Neurologic clinical signs and histologic
lesions of the white matter in humans and dogs suffering
from osmotic demyelination syndromes are somehow
similar to those seen with bromethalin intoxication [3,
13]. With acute bromethalin intoxication changes are
most commonly limited to myelin swelling (intra-myelinic
edema) leading to increased intracranial pressure (e.g.
251 mm water in rats treated at 1 mg/kg compared to
Fig. 4 Likely origin of the two different 543.7 MW (nominal MW 541) bromethalin breakdown products as dehydrofluorodesmethylbromethalin structures
of formula C13H4N3O4F2Br3. The compounds have been given common names of dehydrofluorodesmethylbromethalin-I and –II, which would
be 6-(difluoromethylene)-2,4-dinitro-N-(2,4,6-tribromophenyl)cyclohexa-2,4-dien-1-imine and 8,8-difluoro-3,5-dinitro-(2,4,6-tribromophenyl)-7-
azabicyclo[4.2.0]octa-1,3,5-triene, respectively. Dehydrofluorobromethalin (3,3-difluoro-5,7-dinitro-1-(2,4,6-tribromophenyl)indoline) was not seen and its
absence is significant in light of the apparent lack of formation of a five member ring in deference to a more constrained four member ring
(See figure on previous page.)
Fig. 3 Application of GC-MS/MS bromethalin MRM method. a Bromethalin spiked at 100 ppm into control liver sample. Note bromethalin peak at
17.95-min RT, and principal 543.7 MW breakdown peaks (detected with sensitive m/z 543-derived MRMs) at 16.3-min and 18.6-min retention times,
respectively. b Fat sample collected from our dog. Note that only the 16.3-min bromethalin breakdown compound was present. c Kidney from the
same dog shows the 16.3-min peak and a trace of the 18.6-min peak
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control value 68 mm water) [8] without evidence of mye-
lin loss (as in our case, data not shown). Regarding
osmotic demyelination syndromes, a myelin and oligo-
dendrocyte loss is noted leading to central pontine myeli-
nolysis and/or extrapontine myelinolysis; however clinical
signs that are 2 to 6 days delayed after the swift elevation
of sodium levels are often irreversible or only partially
reversible [13, 14]. The central pontine myelinolysis
lesions in dogs are virtually identical to those of human
cases and the clinical course and manifestations are identi-
cal [15]. Why bromethalin is not inducing oligodendrocyte
and myelin loss is not well understood. According to
chronic and reversibility studies in rats, animals that sur-
vived the acute toxicity phase showed no evidence of mye-
lin or oligodendrocyte loss [8].
The histologic changes induced by bromethalin are
dose dependent [8] and white matter vacuolation can be
minimal or even considered as an autolytic artifact. IHC
for NeuN and GFAP can be utilized to characterize and
confirm subtle changes. NeuN is a neuronal marker that
shows strong reactivity in both surgical and post mortem
samples with little variation in staining intensity regard-
less of routine fixation or autolysis [16]. Decreases in
NeuN reactivity can help to identify a neuronal loss but
is also indicative of metabolic stress/hypoxia [17]. In our
case (Fig. 2) metabolic neuronal stress was likely second-
ary to hemorrhages and brain swelling. Among their
many roles astrocytes play a major function in control-
ling the blood brain barrier efflux [18]. Increased inten-
sity of GFAP immunoreactivity highlighted the marked
increased number of astrocyte processes as well as
increased size of cell bodies (astrocytosis), confirming a
likely pre-mortem osmotic imbalance. Our case illus-
trates how quickly astrocytes can react, revealing marked
evidence of astrocytosis in 2–3 hours (estimated time
between the onset of clinical signs and death).
The meningeal hemorrhages noted in this case were
perplexing as there is no report of meningeal hemorrhage
with bromethalin intoxication. Meningeal hemorrhage
can be seen with severe seizure activity, typically due to
hyperthermia caused by increased muscle activity
combined with a decrease in respiratory mechanism
of cooling. Similarly, meningeal hemorrhage is often
seen in dogs suffering from heatstroke [19]. This dog
was reported to have severe muscle tremors and ri-
gidity and laryngeal function and respiration may
have been compromised potentially leading to hyper-
thermia. An alternative mechanism of hemorrhage
might be attributed to the abrupt natremic status
change. A case report of multiple infants suffering
from salt intoxication reported multiple intracranial
hemorrhages [20], and a report of fatal hypernatremia
in a dog, also found intracranial hemorrhages associ-
ated with thrombosis [21].
Although the efficacy of retrieval of bromethalin residues in
experimental studies is relatively high, in a diagnostic setting
this is not typically the case due to the fact that bromethalin is
rapidly photodegraded under incandescent and fluorescent
light within a matter of hours [3], and because bromethalin
does not seem very stable in tissues (Dr Buchweitz, personal
communication). Neither bromethalin nor the active metab-
olite desmethylbromethalin were identified in any tissues
submitted for toxicologic analysis. If bromethalin intoxica-
tion is suspected, it is important to remember to protect
samples collected for toxicologic analysis from light to pre-
vent or alleviate photodegradation. Identifying surrogate
markers formed from the breakdown of bromethalin ex-
pands the repertoire of molecules available for analysis in the
absence of the parent and active compound. In our case, a
bromethalin product was recovered that is identical to one
proposed by Pasquale-Styles et al. (2006) as arising from
Chemical Ionization during mass spectrometric analysis [4].
This product was identified in the patient’s adipose tissue
and kidney by GC-MS/MS, confirming exposure to bro-
methalin. Unfortunately, the novel dehydrofluorodesmethyl
breakdown product was not recovered from the brain tis-
sue; however, only a portion of brain was submitted for
analysis which might have hindered the detectability.
Treatment recommendations for bromethalin toxicity in-
clude administration of activated charcoal (because of the
enterohepatic circulation) and a lipid emulsion (as the com-
pound is liposoluble) as well as hospitalization and moni-
toring if the dose ingested is expected to result in clinical
signs. The use of osmotic diuretics such as mannitol has
also been recommended at the onset of clinical signs, but is
less commonly administered as its effects are transitory and
cerebrospinal fluid pressures rise when the infusion is
stopped [8]. Idiosyncratic hypernatremia due to activated
charcoal is likely very rare. The use of multiple and low
doses of activated charcoal have been recommended to
lower the risk of idiosyncratic hypernatremia [1]. Veterinar-
ians should also consider strongly recommending in-
hospital monitoring after treatment for bromethalin intoxi-
cation, regardless of the dose ingested and especially if acti-
vated charcoal therapy is deemed necessary.
Conclusions
This complicated case illustrates the difficulty in determin-
ing if the bromethalin alone, the activated charcoal alone,
or the combination of both contributed to the development
of brain lesions. IHC for GFAP and NeuN were helpful in
characterizing subtle changes indicating ante-mortem tissue
reaction. Application of GC-MS/MS to screen for add-
itional surrogate markers such as the reported breakdown
products described herein will be useful in future diagnostic
work-ups in which bromethalin consumption has been ob-
served or is suspected.
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